These findings highlight C3 and C5 as promising candidates for further investigation in the development of dual acetylcholinesterase/monoacylglycerol lipase inhibitors for Alzheimer's disease treatment. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.